Connect your AI

OptimizeRx OPRX Other Contractual Commitments - Due in Remainder of 2025

Other financials

Income statement

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's other contractual commitments - due in remainder of 2025.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is OptimizeRx's other contractual commitments - due in remainder of 2025?: OptimizeRx (OPRX) reported other contractual commitments - due in remainder of 2025 of $11.44M in Q1 2026.
How has OptimizeRx's other contractual commitments - due in remainder of 2025 changed year-over-year?: OptimizeRx's other contractual commitments - due in remainder of 2025 increased by 4.9% year-over-year, from $10.9M to $11.44M.